The Network Pharmacology Company
e-Therapeutics is a drug discovery and development company based in Oxford and Newcastle, UK. The Company is a pioneer of network pharmacology, a distinctive new approach to the discovery of medicines.
e-Therapeutics is listed on AIM with the ticker symbol ETX
Positive Results for ETS2101 trial
e-Therapeutics reports positive interim results from UK phase Ia trial of ETS2101 (dexanabinol) in a variety of solid tumours. The full press release can be found here.
ETS6103 starts phase IIb trial, the full press release can be read here.
Update on ETS2101 phase I trial in brain cancerNo serious drug-related adverse events after five dose escalation steps; patients to be enrolled at higher dose levels.
The full press release can be read here.
e-Therapeutics held a Research and Development presentation for investors and analysts on 27 November.
More details available here.